The action of proteases can be controlled by several mechanisms, including regulation through gene expression; post-translational modifications, such as glycosylation; zymogen activation; targeting specific compartments, such as lysosomes and mitochondria; and blocking proteolysis using endogenous inhibitors. Protease inhibitors are important molecules to be explored for the control of proteolytic processes in organisms because of their ability to act on several proteases. In this context, plants synthesize numerous proteins that contribute to protection against attacks by microorganisms (fungi and bacteria) and/or invertebrates (insects and nematodes) through the inhibition of proteases in these organisms. These proteins are widely distributed in the plant kingdom, and are present in higher concentrations in legume seeds (compared to other organs and other botanical families), motivating studies on their inhibitory effects in various organisms, including humans. In most cases, the biological roles of these proteins have been assigned based mostly on their in vitro action, as is the case with enzyme inhibitors. This review highlights the structural evolution, function, and wide variety of effects of plant Kunitz protease inhibitors, and their potential for pharmaceutical application based on their interactions with different proteases.
ADP-ribosylation is a post-translational modification critical for DNA repair, chromatin remodeling, and cellular stress responses. The enzyme ARH3/ADPRHL2 (encoded by the ADPRS gene) is a member of the ADP-ribosyl-acceptor hydrolase family and plays a pivotal role in the removal of mono-ADP-ribosylation, particularly in response to DNA damage. Variants in the ADPRS gene cause stress-induced childhood-onset neurodegeneration with variable ataxia and seizures (CONDSIAS). Here, we present the case of an 11-year-old Brazilian girl with compound heterozygous variants in ADPRS, including a novel missense variant, c.485T>C; p.Leu162Pro, of unknown clinical significance. This study aimed to determine the pathogenicity of this variant and to test the molecular rationale of using minocycline as a therapeutic strategy for CONDSIAS cases. Clinical identification and diagnosis of the patient was based primarily on MRI and whole exome sequencing. Functional assays were performed in patient fibroblast cell lines using Western blotting and immunofluorescence-based assays and compared with an ARH3 KO cell line generated by CRISPR/Cas9 technology. Our data indicate that the novel p.Leu162Pro variant, combined with a known nonsense variant, c.316C>T; p.Gln106*, causes a severe reduction of ARH3 protein levels in patient fibroblasts. This leads to defective ARH3-dependent removal of ADP-ribosylation, both under basal conditions and following oxidative stress. Our results using minocycline indicate that it is a poor PARP1 inhibitor and was ineffective in reducing basal ADP-ribosylation in ARH3-deficient cells. This study contributes to the growing body of knowledge on ARH3 deficiency associated with CONDSIAS, by identifying a new pathogenic variant and questioning the molecular rationale underlying the therapeutic use of minocycline in patients with CONDSIAS.
Cell death by a non-apoptotic pathway termed parthanatos is induced by hyperactivation of the DNA damage sensor PARP1, which uses NAD + as a substrate to catalyse the poly-ADP-ribosylation (PARylation) of proteins. Parthanatos has been implicated in several pathological conditions such as ischaemia-reperfusion injury and neurodegenerative processes, including Alzheimeŕs and Parkinsońs diseases, as well as rare genetic disorders characterized by PARP1 hyperactivation. However, the precise sequence of molecular events by which excessive PARP1 activity causes cell death is currently unclear. Here we show that, in addition to PARP1-dependent PARylation, the execution of parthanatos also requires the hydrolysis of poly-ADP-ribose (PAR) chains by the glycohydrolase PARG. While complete inhibition of PARG activity prevents parthanatos, low levels of residual PARG activity are sufficient to support cell death by this pathway. Due to a phenotypic discrepancy between CRISPR/Cas9-generated PARG KO cells and PARG inhibitor-treated cells, we uncovered a new PARG splice variant predicted to encode an isoform of 53 kDa, termed PARG53, and provide evidence for the incorrect annotation of the previously reported isoforms PARG55 and PARG60. PARP1 hyperactivation during parthanatos leads to rapid and profound depletion of NAD + and ATP pools, but full PARG inhibition only prevents the depletion of ATP, indicating that the depletion of these core metabolites can be uncoupled, and that ATP depletion is more closely correlated with cell death. This work sheds light on the initial steps of parthanatos induction, demonstrating that PAR formation and PAR hydrolysis are both required for this type of cell death.